The Future of the Global Nuclear Fuel Processing Industry to 2020 by ewghwehws

VIEWS: 3 PAGES: 10

									Hematology Reagents and Analyzers -
Global Pipeline Analysis, Competitive
Landscape and Market
Forecasts to 2017
The Global Hematology Market is expected to grow at a CAGR of 5% from
2010 to 2017
The global hematology market is forecast to grow from $5.7 billion in 2010 to
$8.1 billion by 2017 with a Compound Annual Growth Rate (CAGR) of 5%. The
hemostasis market is the largest segment in terms of market size and
accounted for almost 30% of the total revenue generated from hematology
diagnostics in 2010. Hematology reagents, immunohematology and hematology
rapid tests are the other three segments which contributed major shares in
terms of market size and accounted for about 22%, 19%, and 11% respectively
of the total revenue generated from hematology market in 2010.

The hemostasis segment will continue to witness high growth and remain as the
largest segment in 2010. The global market for hemostasis is forecast to grow
from $1.7 billion in 2010 to about $2.3 billion by 2017, with a CAGR of 5%.
Development in bench-top high throughput hematology analyzers and in high
sensitivity point of care tests will drive the growth in the global hematology
market. Commercialization of innovative products is also likely to drive the future
growth in the market.

The US is the Biggest Market for Hematology
The US market for hematology was valued at $2.8 billion in 2010 and is forecast
to grow at a CAGR of 5% to reach $4 billion in 2017. The US is the biggest
market in the sector, contributing 50% towards the global hematology market in
2010. Hemostasis was valued at $921.7m in 2010. It will continue to be the
largest segment by 2017, growing at an estimated 4% CAGR during the period
2010–2017 to reach $1.2 billion by 2017. The demand for hematology products
in the US is mainly driven by increased awareness about preventive health care
medicine. Furthermore, the market is expected to be driven by the increasing
elderly population, automation and adoption of automated point of care testing
instruments.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haematology-Reagents-
and-Analyzers-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-
Forecasts-to-
2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medic
al_Devices

The Shift to Preventive Medicine and Rising Levels of Basic Healthcare is
Driving the Hematology Market
The US is implementing healthcare reforms centered on preventive healthcare
to overcome the burden of rising healthcare costs. The healthcare reform bill
‘Affordable Care Act’ passed in the US in March 2010 is expected to greatly
reduce the number of uninsured people in the country. This reform is expected to
increase the percentage of people with medical insurance from about 80% at
present to more than 90%. The ‘Affordable Care Act’ also encourages hospitals
and providers to find new ways to provide higher quality care and avoid
unnecessary hospital readmissions. Furthermore, the US government is adapting
programs of preventive care for chronic diseases. The overall objective of these
reforms is to invest more in preventive medicine, thereby decreasing the number
of hospitalizations and the overall cost of care.

Similarly, an increasing number of governments in emerging markets are
increasing efforts to raise their levels of basic healthcare. The healthcare reforms
in China that commenced in 2009 involve an investment of $124 billion in public
healthcare services over a three year period. Furthermore, in April 2008, Japan
introduced a new system of specific health checks and specific healthcare
education, aimed at insured individuals aged between 40 and 74 years. The
implementation of these reforms will make basic healthcare undergo changes on
a global basis. At the same time as this, the shift in preventive medicine and
reforms in basic healthcare provide a huge opportunity for the diagnostic market.
Overall the diagnostic testing sector, which includes hematology, is expected to
play an important role in healthcare, thereby driving the hematology market.
Hematology Market is Expected to Experience Higher Growth Rates in Emerging
Countries (China, India and Brazil) in the Future
China, India and Brazil are three emerging economies that are spending more
than $2.5 billion per year on In Vitro Diagnostic (IVD) products. The hematology
markets in these emerging economies are forecast to grow at a CAGR of 14%,
16% and 8% respectively during the period 2010–2017. The growth in these
economies will be driven by increasing population, significant market potential,
increasing health care expenditure and growing affordability for private medical
care.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haematology-Reagents-
and-Analyzers-Global-Pipeline-Analysis-Competitive-Landscape-and-Market-
Forecasts-to-
2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medica
l_Devices

Clinical Labs and Diagnostic Medicine
Both the Brazilian and Indian government follow a similar stratified structure to
provide access to medical services for their populations. The public sector clinics
and hospitals are strapped for cash and always poorly funded. In recent times
there has been an increasing investment in private health care infrastructure in
these countries, specifically corporate hospitals and commercial labs. Private
hospitals have there own internal institutional review boards and ethical
committees, thus have a greater advantage over government hospitals in fast
tracking decisions, making them a focused target for many international IVD
firms.

In China, there is a less existence of private medicine in any form. Once the
government clarifies its position on regulation of private medicine then there will
be a significant growth in the commercial lab business. The private sector of
the Chinese diagnostic market which includes hematology is completely
unoccupied and it provides a great market opportunity for IVD companies.

IVD Technical Competence is high in Emerging (China, India, and Brazil)
Countries
In India and China the local facilities and development assets, particularly in
private healthcare, are increasing rapidly. In India the private laboratory chains
are thriving in metropolitan cities. SRL Ranbaxy has significant processing labs
in Mumbai, Delhi, and the other major cities of India and collects samples from
350 towns countrywide. Dr. Lal Path Labs has 27 labs and collects diagnostic
samples from 250 towns across the country. Although foreign companies have
not entered the private lab market in a significant way there, Quest Diagnostics
recently opened a large facility in New Delhi, India.

Along with that there is plenty of technical competence in all three countries,
due to which these markets are not suitable for me-too products. Innovative
products and competitive pricing would play a crucial role for any foreign
players looking to enter into this market. The type of diagnostic instruments
required by these countries during the next five to seven years will not be the
same as those required by the developed markets. So the companies venturing
into these markets should consider these points and design suitable diagnostic
systems for these countries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haematology-
Reagents-and-Analyzers-Global-Pipeline-Analysis-Competitive-Landscape-
and-Market-Forecasts-to-
2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medi
cal_Devices

Beckman Coulter, Sysmex and Roche were the Leading Players in the
Global Hematology Market in 2009
In 2009, Beckman Coulter was the leading player in the global hematology
market with a share of 15%. Sysmex Corporation and Roche also have a
significant presence in the global hematology market with a market share of
13% and 12%, respectively.

Beckman Coulter holds the competitive advantage in the hematology market
due to its advanced technology, high automation and strong brand recognition.
The Beckman product portfolio in the hematology market includes the LH 1500
Series hematology automation solutions, UniCel DxH cellular analysis system,
Coulter Ac.T family of hematology analyzers and Coulter LH series automated
hematology analyzers. Furthermore, the UniCel DxH slidemaker and stainer is
waiting for marketing approval in Europe and Canada. It is designed to
facilitate automation of slide making and staining in hematology laboratories.
UniCel DxH product is expected to receive approval by the end of 2011 in
Canada and Europe. It is expected that the marketing approval in these
regions will further increase the overall market share of Beckman Coulter in
the global hematology market.

Sysmex and Roche also have a strong presence in the market due to their
advanced product portfolio of hematology diagnostics. Sysmex offer XS, XT
and XT series of automated hematology analyzers and point of care testing
instruments. Roche offers Accu-Chek, CoaguChek, Cobas, Confirm and the
LightCycler series of coagulation analyzers and hematology automation
systems.

Currently, the hematology market is congregated by a significant number of
small players. However, it is expected that the reforms implemented by the
developed and emerging economies will bring a change on a global basis,
thereby further opening the market to new entrants. As there are few barriers to
the entry of new players into the market, it could see heightened competitive
intensity due to multiple product launches.

GlobalData’s new report, “Hematology Reagents and Analyzers - Global
Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017”
provides key data, information and analysis on the global hematology market.
The report provides market landscape, competitive landscape and market
trends information on the hematology market. The report provides
comprehensive information on the key trends affecting the market, and key
analytical content on the market dynamics. The report also reviews the
competitive landscape and technology offerings.

This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Haematology-
Reagents-and-Analyzers-Global-Pipeline-Analysis-Competitive-Landscape-
and-Market-Forecasts-to-
2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Medi
cal_Devices

Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe:                        +44 207 753 4299
                               +44 1204 543 533
Asia Pacific:                  +91 40 6616 6782

								
To top